147 related articles for article (PubMed ID: 32142715)
21. Effect of solubilizing and microemulsifying excipients in polyethylene glycol 6000 solid dispersion on enhanced dissolution and bioavailability of ketoconazole.
Heo MY; Piao ZZ; Kim TW; Cao QR; Kim A; Lee BJ
Arch Pharm Res; 2005 May; 28(5):604-11. PubMed ID: 15974450
[TBL] [Abstract][Full Text] [Related]
22. A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development.
Martinez MN; Wu F; Sinko B; Brayden DJ; Grass M; Kesisoglou F; Stewart A; Sugano K
AAPS J; 2022 May; 24(3):61. PubMed ID: 35501528
[TBL] [Abstract][Full Text] [Related]
23. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
24. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
25. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
Chen ML
Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
[TBL] [Abstract][Full Text] [Related]
27. The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment.
Khoo SM; Porter CJ; Charman WN
Int J Pharm; 2000 Sep; 205(1-2):65-78. PubMed ID: 11000543
[TBL] [Abstract][Full Text] [Related]
28. Effects of frequently used pharmaceutical excipients on the organic cation transporters 1-3 and peptide transporters 1/2 stably expressed in MDCKII cells.
Otter M; Oswald S; Siegmund W; Keiser M
Eur J Pharm Biopharm; 2017 Mar; 112():187-195. PubMed ID: 27903454
[TBL] [Abstract][Full Text] [Related]
29. Excipients with specialized functions for effective drug delivery.
Hamman J; Steenekamp J
Expert Opin Drug Deliv; 2012 Feb; 9(2):219-30. PubMed ID: 22196483
[TBL] [Abstract][Full Text] [Related]
30. Targeting intestinal transporters for optimizing oral drug absorption.
Varma MV; Ambler CM; Ullah M; Rotter CJ; Sun H; Litchfield J; Fenner KS; El-Kattan AF
Curr Drug Metab; 2010 Nov; 11(9):730-42. PubMed ID: 21189135
[TBL] [Abstract][Full Text] [Related]
31. Impact of Solubilizing Additives on Supersaturation and Membrane Transport of Drugs.
Raina SA; Zhang GG; Alonzo DE; Wu J; Zhu D; Catron ND; Gao Y; Taylor LS
Pharm Res; 2015 Oct; 32(10):3350-64. PubMed ID: 26017301
[TBL] [Abstract][Full Text] [Related]
32. Effect of excipients on oral absorption process according to the different gastrointestinal segments.
Ruiz-Picazo A; Lozoya-Agullo I; González-Álvarez I; Bermejo M; González-Álvarez M
Expert Opin Drug Deliv; 2021 Aug; 18(8):1005-1024. PubMed ID: 32842776
[TBL] [Abstract][Full Text] [Related]
33. Oral Absorption Promoters: Opportunities, Issues, and Challenges.
Yewale C; Patil S; Kolate A; Kore G; Misra A
Crit Rev Ther Drug Carrier Syst; 2015; 32(5):363-87. PubMed ID: 26559432
[TBL] [Abstract][Full Text] [Related]
34. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations.
Beg S; Swain S; Rizwan M; Irfanuddin M; Malini DS
Curr Drug Deliv; 2011 Nov; 8(6):691-702. PubMed ID: 21864253
[TBL] [Abstract][Full Text] [Related]
35. The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update.
Zhang W; Li Y; Zou P; Wu M; Zhang Z; Zhang T
AAPS J; 2016 Jul; 18(4):830-43. PubMed ID: 27184579
[TBL] [Abstract][Full Text] [Related]
36. Sex-Dependence in the Effect of Pharmaceutical Excipients: Polyoxyethylated Solubilising Excipients Increase Oral Drug Bioavailability in Male but not Female Rats.
Mai Y; Dou L; Madla CM; Murdan S; Basit AW
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31083453
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal absorption II. Formulation factors affecting drug bioavailability.
Blanchard J
Am J Pharm Sci Support Public Health; 1978; 150(5):132-51. PubMed ID: 364993
[No Abstract] [Full Text] [Related]
38. The Solubility-Permeability Interplay for Solubility-Enabling Oral Formulations.
Nainwal N; Singh R; Jawla S; Saharan VA
Curr Drug Targets; 2019; 20(14):1434-1446. PubMed ID: 31333138
[TBL] [Abstract][Full Text] [Related]
39. Enhanced aqueous solubility and bioavailability of capsaicin by the preparation of an inclusion complex.
Chen X; Sun X; Ren K; Zhang X; Zhang Z; Gong T
Arzneimittelforschung; 2010; 60(9):571-4. PubMed ID: 21117501
[TBL] [Abstract][Full Text] [Related]
40. Boosting drug bioavailability in men but not women through the action of an excipient.
Mai Y; Ashiru-Oredope DAI; Yao Z; Dou L; Madla CM; Taherali F; Murdan S; Basit AW
Int J Pharm; 2020 Sep; 587():119678. PubMed ID: 32710919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
